The Effect of Enoxaparin and Aspirin in Preventing Miscarriage in Women with Polycystic Ovary Syndrome with a History of Two or More Recurrent Abortion without Acquired Thrombophilia

Document Type : Original Article

Authors

1 Associate Professor, Department of Obstetrics and Gynecology, Clinical Research Development Unit, Besat Hospital, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.

2 General Physician, Clinical Research Development Unit, Besat Hospital, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.

3 Associate Professor, Department of Epidemiology, Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.

10.22038/ijogi.2025.78202.6019

Abstract

Introduction: Recurrent abortion is one of the problems of reproductive medicine and its prevalence is higher in women with polycystic ovarian syndrome (PCOS). Although anticoagulants and aspirin are commonly used for treatment, there is not enough evidence to support the effectiveness of the treatment. This study was conducted with aim to evaluate the effect of aspirin and enoxaparin on the prevention of recurrent abortion in patients with PCOS.
Methods: This retrospective cohort study was conducted in 2017-2018 on 40 women aged 20-40 years with polycystic ovary syndrome (PCOS) and a history of two or more recurrent abortion who achieved pregnancy following ovulation induction therapy for infertility. After ovulation induction and confirming an intrauterine pregnancy, the patients were divided into two groups: Enoxaparin and control. Both groups were received aspirin from the third month of gestation. Then, pregnancy outcomes were compared between the two groups and were followed-up. Data analysis was performed using SPSS (version 17) and Mann-Whitney, Chi-square, and Fisher’s exact tests. P<0.05 was considered statistically significant.
Results: There was no statistically significant difference between the two groups in terms of age, number of pregnancies, delivery, and miscarriage. In the enoxaparin and aspirin group, 16 individuals (80%) had full-term delivery compared to 12 individuals (60%) in the aspirin group, although the difference was not statistically significant (P=0.3).
Conclusion: In women with polycystic ovary syndrome, the group receiving enoxaparin and aspirin experienced approximately a 20% reduction in recurrent abortion. Although the results were not statistically significant due to the small sample size, they have clinical value and warrant further investigation.

Keywords

Main Subjects

References

  1. Chakraborty P, Goswami SK, Rajani S, Sharma S, Kabir SN, Chakravarty B, et al. Recurrent pregnancy loss in polycystic ovary syndrome: role of hyperhomocysteinemia and insulin resistance. PloS one 2013; 8(5):e64446.
  2. Jeve YB, Davies W. Evidence-based management of recurrent miscarriages. Journal of human reproductive sciences 2014; 7(3):159-69.
  3. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E. American Association of Clinical Endocrinologists, American College of Endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome-part 1. Endocrine Practice 2015; 21(11):1291-300.
  4. Ashaq L, Al Mazer Y, Al Qahtani N. Recurrent pregnancy loss in patients with polycystic ovary syndrome: a case control study. Open Journal of Obstetrics and Gynecology 2017; 7(11):1073-85.
  5. Nouri N, Ghasemi HF, Dehghan J, Ghasemi M. Frequency of various factors affecting pregnancy loss in patients with history of recurrent pregnancy loss in Sistan and Balouchestan province 2017-2018; 2023.
  6. Elenis E, Desroziers E, Persson S, Sundström Poromaa I, Campbell RE. Early initiation of anti-androgen treatment is associated with increased probability of spontaneous conception leading to childbirth in women with polycystic ovary syndrome: a population-based multiregistry cohort study in Sweden. Human Reproduction 2021; 36(5):1427-35.
  7. Vannuccini S, Clifton VL, Fraser IS, Taylor HS, Critchley H, Giudice LC, et al. Infertility and reproductive disorders: impact of hormonal and inflammatory mechanisms on pregnancy outcome. Human reproduction update 2016; 22(1):104-15.
  8. Pan ML, Chen LR, Chen KH. The risk of subsequent miscarriage in pregnant women with prior polycystic ovarian syndrome: A nationwide population-based study. International journal of environmental research and public health 2021; 18(16):8253.
  9. Ali AE, Ibrahim SA, Mohammed R, Zaitoun MM. The Prevalence of Polycystic Ovary Syndrome among women with History of Recurrent Miscarriage. Journal of Cardiovascular Disease Research 2021; 12(4):2135-43.
  10. Sun YF, Zhang J, Xu YM, Cao ZY, Wang YZ, Hao GM, et al. High BMI and insulin resistance are risk factors for spontaneous abortion in patients with polycystic ovary syndrome undergoing assisted reproductive treatment: a systematic review and meta-analysis. Frontiers in endocrinology 2020; 11:592495.
  11. Banu J, Fatima P, Sultana P, Chowdhury MA, Begum N, Anwary SA, et al. Association of infertile patients having polycystic ovarian syndrome with recurrent miscarriage. Mymensingh Medical Journal: MMJ 2014; 23(4):770-3.
  12. Liu F, Shi D, Jin R, Yu X. Clinical efficacy and adverse effects of LMWH combined with ASA in the treatment of RSA: A meta-analysis and systematic review. Medicine 2024; 103(37):e39603.
  13. Elmahashi MO, Elbareg AM, Essadi FM, Ashur BM, Adam I. Low dose aspirin and low-molecular-weight heparin in the treatment of pregnant Libyan women with recurrent miscarriage. BMC research notes 2014; 7:1-4.
  14. De Jong PG, Kaandorp S, Di Nisio M, Goddijn M, Middeldorp S. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database of Systematic Reviews 2014(7).
  15. Baldacci S, Santoro M, Mezzasalma L, Pierini A, Coi A. Medication use during pregnancy and the risk of gastroschisis: a systematic review and meta-analysis of observational studies. Orphanet Journal of Rare Diseases 2024; 19(1):31.
  16. Schisterman EF, Silver RM, Lesher LL, Faraggi D, Wactawski-Wende J, Townsend JM, et al. Preconception low-dose aspirin and pregnancy outcomes: results from the EAGeR randomised trial. The Lancet 2014; 384(9937):29-36.
  17. Kaandorp SP, Goddijn M, Van Der Post JA, Hutten BA, Verhoeve HR, Hamulyák K, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. New England Journal of Medicine 2010; 362(17):1586-96.
  18. Pasquier E, de Saint Martin L, Bohec C, Chauleur C, Bretelle F, Marhic G, et al. Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial. Blood, The Journal of the American Society of Hematology 2015; 125(14):2200-5.
  19. Wartena R, Matjila M. Polycystic ovary syndrome and recurrent pregnancy loss, a review of literature. Frontiers in endocrinology 2023; 14:1183060.
  20. Egerup P, Nielsen HS, Andersen AN, Christiansen OB. Live birth rate in women with recurrent pregnancy loss after in vitro fertilization with concomitant intravenous immunoglobulin and prednisone. Journal of Clinical Medicine 2022; 11(7):1894.
  21. Li J, Gao YH, Xu L, Li ZY. Meta‐analysis of heparin combined with aspirin versus aspirin alone for unexplained recurrent spontaneous abortion. International Journal of Gynecology & Obstetrics 2020; 151(1):23-32.
The Iranian Journal of Obstetrics, Gynecology and Infertility
Volume 28, Issue 4
June 2025
Pages 10-18

Files

Share

How to cite

Statistics